Devesh Rai, MD

DocwireNews

Cost-effective analysis of the Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial(REDUCE-IT) revealed more incremental quality-adjusted life-years (QALYs) during the trial and adjusted during the lifetime, according to a recent study published in JAMA Network.1The REDUCE-IT trial enrolled patients with hypertriglyceridemia and high-risk patients and history of cardiovascular disease or diabetes along with at least one other risk factor and already on statins and randomized among 4 gm/day of icosapent ethyl (IPE) and placebo. The trial enrolled 8179 patients(4089 in IPE, 4090 in placebo arm) with a median follow up of 4.9 years, revealing a reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina in the IPE arm (HR:0.75, CI: 0.68-0.83, p&lt;0.0001) and number needed to treat of 21.2The cost-effectiveness of IPE has been questioned; authors performed cost-effectiveness analysis from patient-based data, revealing IPE group with more QALYs during the trial (3.34 vs. 3.27) and lifetime projections (10.59 vs. 10.35) than placebo arm.Interestingly, total health care cost was higher in the IPE arm during the period of trial than standard of care. Nevertheless, However, IPE arm had higher (3.34) QALY than standard of care (3.27) and this effect continued over lifetime projections as well(10.59 for IPE vs 10.25). IPE was found to be cost effective ($195,276) than standard of care ($197,064) at a mean difference of -$1788 (95% CI: -$9735-$6159) using SSR cost during lifetime. However, when comparing the wholesale acquisition cost (WAC), IPE was costly ($202,830) than standard of care ($197,064) with mean difference of $5766 (95% CI, $1094-$10,438) over lifetime.1Overall, IPE was cheaper and cost-effective revealing, a 58.4% lifetime probability of costing less and 89.4% and 72.5% probability of costing less than $50,000 per QALY using SSR and WAC cost respectively.This is a unique study shedding light on the cost effectiveness of IPE over lifetime in high-risk patients which will be helpful in primary and secondary prevention of cardiovascular diseases.Lead principal investigator of REDUCE-IT trial, Dr. Deepak L. Bhatt, &nbsp;Executive Director of Interventional Cardiovascular Programs at Brigham and Women&rsquo;s Hospital and Professor of Medicine at Harvard Medical Schoool says, &ldquo;This analysis from REDUCE-IT finds that icosapent ethyl is highly cost-effective. Coupled with the large reductions in cardiovascular events, these data provide a strong rationale to icosapent ethyl in all eligible patients.&rdquo;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

The Lifetime Worth of Icosapent Ethyl: A Cost Effective Analysis of REDUCE-IT

Cardionerds is an entertaining and educational medical cardiology podcast created by three cardiologists. They want to bring high yield cardiovascular concepts in a fun and engaging format for their listeners of all levels. Click below to learn more!

CardioNerds

Cost-effective analysis of the Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial(REDUCE-IT) revealed more incremental quality-adjusted life-years ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe